Annual report pursuant to Section 13 and 15(d)

Segments

v3.8.0.1
Segments
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segments
Segments
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of BioReference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2017
 
2016
 
2015
Revenue from services:
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

Diagnostics
889,076

 
1,012,129

 
329,599

Corporate

 

 
140

 
$
889,076

 
$
1,012,129

 
$
329,739

Revenue from products:
 
 
 
 
 
Pharmaceutical
$
107,759

 
$
83,467

 
$
80,146

Diagnostics

 

 

Corporate

 

 

 
$
107,759

 
$
83,467

 
$
80,146

Revenue from transfer of intellectual property:
 
 
 
 
 
Pharmaceutical
$
70,668

 
$
126,065

 
$
81,853

Diagnostics

 

 

Corporate

 

 

 
$
70,668

 
$
126,065

 
$
81,853

Operating loss:
 
 
 
 
 
Pharmaceutical
$
(87,907
)
 
$
(9,841
)
 
$
(40,395
)
Diagnostics
(136,540
)
 
(3,393
)
 
(10,294
)
Corporate
(55,615
)
 
(60,041
)
 
(46,512
)
Less: Operating loss attributable to noncontrolling interests

 

 
(1,280
)
 
$
(280,062
)
 
$
(73,275
)
 
$
(98,481
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceutical
$
27,513

 
$
18,254

 
$
10,245

Diagnostics
74,442

 
78,233

 
31,918

Corporate
138

 
89

 
85

 
$
102,093

 
$
96,576

 
$
42,248

Income (loss) from investment in investees:
 
 
 
 
 
Pharmaceutical
$
(12,646
)
 
$
(7,665
)
 
$
(7,105
)
Diagnostics
(1,825
)
 
13

 

Corporate

 

 

 
$
(14,471
)
 
$
(7,652
)
 
$
(7,105
)
Revenues:
 
 
 
 
 
United States
$
908,971

 
$
1,014,389

 
$
344,464

Ireland
77,285

 
137,785

 
78,989

Chile
44,286

 
35,364

 
29,885

Spain
18,285

 
15,812

 
16,622

Israel
13,951

 
15,317

 
18,107

Mexico
4,605

 
2,988

 
3,671

Other
120


6

 

 
$
1,067,503

 
$
1,221,661

 
$
491,738


(In thousands)
December 31,
2017
 
December 31,
2016
Assets:
 
 
 
Pharmaceutical
$
1,282,564

 
$
1,294,916

Diagnostics
1,241,388

 
1,408,522

Corporate
60,604

 
63,181

 
$
2,584,556

 
$
2,766,619

Goodwill:
 
 
 
Pharmaceutical
$
264,313

 
$
251,817

Diagnostics
452,786

 
452,786

Corporate

 

 
$
717,099

 
$
704,603


During the year ended December 31, 2017, two customers represented more than 10% of our total consolidated revenue. During the year ended December 31, 2016, no customer represented more than 10% of our total consolidated revenue. During the year ended December 31, 2015, revenue recognized under the Pfizer Transaction represented 13% of our total consolidated revenue. As of December 31, 2017, no customer represented more than 10% of our accounts receivable balance. As of December 31, 2016, one customer represented more than 10% of our accounts receivable balance.
The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 
(In thousands)
December 31, 2017
 
December 31, 2016
PP&E:
 
 
 
U.S.
$
89,114

 
$
100,716

Foreign
57,443

 
22,115

Total
$
146,557

 
$
122,831